Progress in understanding the genomic basis for adverse drug reactions: A comprehensive review and focus on the role of ethnicity

Pharmacogenomics

Volumn 16, Issue 10, 2015, Pages 1161-1178

  Chan, Sze Ling ^a   Jin, Shengnan ^a   Loh, Marie ^a   Brunham, Liam R ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b Dept Medicine Endocrinol Diabet   (Singapore)

Author keywords

Adverse drug reactions; common diseases; ethnic diversity; genome wide association studies; HLA; pharmacogenomics

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT; AROMATASE INHIBITOR; ASPARAGINASE; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CARBAMAZEPINE; CISPLATIN; CITALOPRAM; CLOZAPINE; DAPSONE; HYDROCHLOROTHIAZIDE; LUMIRACOXIB; MERCAPTOPURINE; NEUROLEPTIC AGENT; NEVIRAPINE; PACLITAXEL; PEGINTERFERON; PENICILLIN DERIVATIVE; PHENYTOIN; RIBAVIRIN; RISPERIDONE;

ADVERSE DRUG REACTION; AGRANULOCYTOSIS; ALLERGY; DRUG RESEARCH; ETHNIC DIFFERENCE; ETHNICITY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HEARING DISORDER; HEARING IMPAIRMENT; HEMOLYTIC ANEMIA; HIP DISEASE; HUMAN; HYPERSENSITIVITY; HYPERTENSION; HYPERURICEMIA; JAW OSTEONECROSIS; LEUKOPENIA; LIVER INJURY; MUSCULOSKELETAL DISEASE; NEUROPATHY; NEUTROPENIA; PANCREATITIS; PHARMACOGENOMICS; PHENOTYPE; RASH; RESPIRATORY TRACT DISEASE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SAMPLE SIZE; SEXUAL DYSFUNCTION; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; SUICIDAL IDEATION; THROMBOCYTOPENIA; TORSADE DES POINTES; TOXIC EPIDERMAL NECROLYSIS; VISUAL DISORDER; WEIGHT GAIN; ETHNIC GROUP; GENETIC VARIATION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; PHARMACOGENETICS; PROCEDURES;

DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ETHNIC GROUPS; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; HUMANS; PHARMACOGENETICS;

EID: 84941622230     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/PGS.15.54     Document Type: Review

References (130)

1. Daly AK. Genome-wide association studies in pharmacogenomics. Nat. Rev. Genet. 11(4), 241-246 (2010).
2. GWAS catalog. www.genome.gov/gwastudies
3. Tohkin M, Kaniwa N, Saito Y et al. A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Pharmacogenomics J. 13(1), 60-69 (2013).
4. Génin E, Schumacher M, Roujeau J-C et al. Genome-wide association study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Europe. Orphanet J. Rare Dis. 6(1), 52 (2011).
5. Lucena MI, Molokhia M, Shen Y et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 141(1), 338-347 (2011).
6. Behr ER, Ritchie MD, Tanaka T et al. Genome wide analysis of drug-induced torsades de pointes: Lack of common variants with large effect sizes. PLoS ONE 8(11), e78511 (2013).
7. Menke A, Domschke K, Czamara D et al. Genome-wide association study of antidepressant treatment-emergent suicidal ideation. Neuropsychopharmacology 37(3), 797-807 (2012).
8. Clark SL, Adkins DE, Aberg K et al. Pharmacogenomic study of side-effects for antidepressant treatment options in STAR D. Psychol. Med. 42(06), 1151-1162 (2012).
9. Kurose K, Hiratsuka K, Ishiwata K et al. Genome-wide association study of SSRI/SNRI-induced sexual dysfunction in a Japanese cohort with major depression. Psychiatry Res. 198(3), 424-429 (2012).
10. Ingle JN, Schaid DJ, Goss PE et al. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J. Clin. Oncol. 28(31), 4674-4682 (2010).
11. Chen S-H, Pei D, Yang W et al. Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity. Clin. Pharmacol. Ther. 88(2), 191-196 (2010).
12. Park BL, Kim T-H, Kim J-H et al. Genome-wide association study of aspirin-exacerbated respiratory disease in a Korean population. Hum. Genet. 132(3), 313-321 (2013).
13. Schneider BP, Li L, Shen F et al. Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. Br. J. Cancer. 111, 1241-1248 (2014).
14. Nicoletti P, Cartsos VM, Palaska PK, Shen Y, Floratos A, Zavras AI. Genomewide pharmacogenetics of bisphosphonateinduced osteonecrosis of the jaw: the role of RBMS3. Oncologist 17(2), 279-287 (2012).
15. McCormack M, Alfirevic A, Bourgeois S et al. HLA-A∗3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N. Engl. J. Med. 364(12), 1134-1143 (2011).
16. Ozeki T, Mushiroda T, Yowang A et al. Genome-wide association study identifies HLA-A∗3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum. Mol. Genet. 20(5), 1034-41 (2011).
17. Low S-K, Chung S, Takahashi A et al. Genome-wide association study of chemotherapeutic agent-induced severe neutropenia/leucopenia for patients in Biobank Japan. Cancer Sci. 104(8), 1074-1082 (2013).
18. Srinivasan Y, Sasa M, Honda J et al. Genome-wide association study of epirubicin-induced leukopenia in Japanese patients. Pharmacogenet. Genomics 21(9), 552-558 (2011).
19. Chung S, Low S-K, Zembutsu H et al. A genome-wide association study of chemotherapy-induced alopecia in breast cancer patients. Breast Cancer Res. 15(5), R81 (2013).
20. Xu H, Robinson GW, Huang J et al. Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. Nat. Genet. 47(3), 263-266. (2015).
21. Adkins DE, Clark SL, Åberg K et al. Genome-wide pharmacogenomic study of citalopram-induced side effects in STARD. Transl. Psychiatry 2, e129 (2012).
22. Goldstein JI, Jarskog LF, Hilliard C et al. Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles. Nat. Commun. 5, 4757 (2014).
23. Zhang FR, Liu H, Irwanto A et al. HLA-B∗13:01 and the dapsone hypersensitivity syndrome. N. Engl. J. Med. 369(17), 1620-1628 (2013).
24. Vandell a. G, Mcdonough CW, Gong Y et al. Hydrochlorothiazide-induced hyperuricaemia in the pharmacogenomic evaluation of antihypertensive responses study. J. Intern. Med. 276(5), 486-497 (2014).
25. Singer JB, Lewitzky S, Leroy E et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat. Genet. 42(8), 711-714 (2010).
26. Chantarangsu S, Mushiroda T, Mahasirimongkol S et al. Genome-wide association study identifies variations in 6p21. 3 associated with nevirapine-induced rash. Clin. Infect. Dis. 53(4), 341-348 (2011).
27. Baldwin R, Owzar K, Zembutsu H et al. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin. Cancer Res. 18(18), 5099-5109 (2012).
28. Leandro-Garciá LJ, Inglada-Pérez L, Pita G et al. Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy. J. Med. Genet. 50(9), 599-605 (2013).
29. Fellay J, Thompson AJ, Ge D et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 464(7287), 405-408 (2010).
30. Ochi H, Maekawa T, Abe H et al. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy-a genome-wide study of Japanese HCV virus patients. Gastroenterology 139(4), 1190-1197 (2010).
31. Thompson AJ, Clark PJ, Singh A et al. Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. J. Hepatol. 56(2), 313-319 (2012).
32. Tanaka Y, Kurosaki M, Nishida N et al. Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C. Hum. Mol. Genet. 20(17), 3507-3516 (2011).
33. Iio E, Matsuura K, Nishida N et al. Genome-wide association study identifies a PSMD3 variant associated with neutropenia in interferon-based therapy for chronic hepatitis C. Hum. Genet. 134, 279-289 (2014).
34. Gueánt J-L, Romano A, Cornejo-Garcia J-A et al. HLADRA variants predict penicillin allergy in genome-wide fine-mapping genotyping. J. Allergy Clin. Immunol. 135(1), 253-259 (2015).
35. Chung W-H, Chang W-C, Lee Y-S et al. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. JAMA 312(5), 525-534 (2014).
36. Adkins DE, Aberg K, McClay JL et al. Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. Mol. Psychiatry 16(3), 321-332 (2011).
37. Malhotra AK, Correll CU, Chowdhury NI et al. Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch. Gen. Psychiatry 69(9), 904-912 (2012).
38. Heap G a, Weedon MN, Bewshea CM et al. HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nat. Genet. 46(10), 1131-1134 (2014).
39. Yang S-K, Hong M, Baek J et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat. Genet. 46(9), 1017-1020 (2014).
40. Shen Y, Nicoletti P, Floratos A et al. Genome-wide association study of serious blistering skin rash caused by drugs. Pharmacogenomics J. 12(2), 96-104 (2012).
41. Nelson MR, Bacanu S, Mosteller M et al. Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions. Pharmacogenomics J. 9(1), 23-33 (2009).
42. Pichler WJ. Delayed drug hypersensitivity reactions. Ann. Intern. Med. 139(8), 683-693 (2003).
43. Daly AK. Using genome-wide association studies to identify genes important in serious adverse drug reactions. Annu. Rev. Pharmacol. Toxicol. 52(1), 21-35 (2012).
44. Hetherington S, Hughes AR, Mosteller M et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359(9312), 1121-1122 (2002).
45. Chan, Jin, Loh & Brunham 45 Mallal S, Nolan D, Witt C et al. Association between presence of HLA-B∗5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359(9308), 727-732 (2002).
46. Mallal S, Phillips E, Carosi G et al. HLA-B∗5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358(6), 568-579 (2008).
47. Rauch A, Nolan D, Thurnheer C et al. Refining abacavir hypersensitivity diagnoses using a structured clinical assessment and genetic testing in the Swiss HIV Cohort Study. Antivir. Ther. 13(8), 1019-1028 (2008).
48. Young B, Squires K, Patel P et al. First large, multicenter, open-label study utilizing HLA-B∗5701 screening for abacavir hypersensitivity in North America. AIDS 22(13), 1673-1675 (2008).
49. Chung W-H, Hung S-I, Hong H-S et al. A marker for Stevens-Johnson syndrome. Nature 428, 486 (2004).
50. Locharernkul C, Loplumlert J, Limotai C et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B∗1502 allele in Thai population. Epilepsia 49, 2087-2091 (2008).
51. Tassaneeyakul W, Tiamkao S, Jantararoungtong T et al. Association between HLA-B∗1502 and carbamazepineinduced severe cutaneous adverse drug reactions in a Thai population. Epilepsia 51, 926-930 (2010).
52. Ding WY, Lee CK, Choon SE. Cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia. Int. J. Dermatol. 49, 834-841 (2010).
53. Maurano MT, Humbert R, Rynes E et al. Systematic localization of common disease-associated variation in regulatory DNA. Science 337(6099), 1190-1195 (2012).
54. SEARCH Collaborative Group, Link E, Parish S et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N. Engl. J. Med. 359(8), 789-799 (2008).
55. Voora D, Shah SH, Spasojevic I et al. The SLCO1B1∗5 genetic variant is associated with statin-induced side effects. J. Am. Coll. Cardiol. 54, 1609-1616 (2009).
56. Brunham LR, Lansberg PJ, Zhang L et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J. 12(3), 233-237 (2012).
57. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet. Genomics 16(12), 873-879 (2006).
58. Chen C-H, Lee C-S, Lee M-TM et al. Variant GADL1 and response to lithium therapy in bipolar I disorder. N. Engl. J. Med. 370(2), 119-128 (2014).
59. Schaub MA, Boyle AP, Kundaje A, Batzoglou S, Snyder M. Linking disease associations with regulatory information in the human genome. Genome Res. 22(9), 1748-1759 (2012).
60. Boyle AP, Hong EL, Hariharan M et al. Annotation of functional variation in personal genomes using RegulomeDB. Genome Res. 22(9), 1790-1797 (2012).
61. Gamazon ER, Perera M. Genome-wide approaches in pharmacogenomics: heritability estimation and pharmacoethnicity as primary challenges. Pharmacogenomics 13(10), 1101-1104 (2012).
62. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3(2), 229-243 (2002).
63. Chowbay B, Zhou S, Lee EJD. An interethnic comparison of polymorphisms of the genes encoding drug-metabolizing enzymes and drug transporters: experience in Singapore. Drug Metab. Rev. 37(2), 327-378 (2005).
64. Cropp CD, Yee SW, Giacomini KM. Genetic variation in drug transporters in ethnic populations. Clin. Pharmacol. Ther. 84(3), 412-416 (2008).
65. Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet. Genomics 17(2), 93-101 (2007).
66. Solus JF, Arietta BJ, Harris JR et al. Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 5(7), 895-931 (2004).
67. Man M, Farmen M, Dumaual C et al. Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major east Asian subpopulations with comparison to Caucasians and Africans. J. Clin. Pharmacol. 50(8), 929-940 (2010).
68. Ramos E, Doumatey A, Elkahloun AG et al. Pharmacogenomics, ancestry and clinical decision making for global populations. Pharmacogenomics J. 14(3), 217-222 (2014).
69. Brunham LR, Chan SL, Li R et al. Pharmacogenomic diversity in Singaporean populations and Europeans. Pharmacogenomics J. 14(6), 555-563 (2014).
70. Aminkeng F, Ross CJD, Rassekh SR et al. Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent. Pharmacogenomics J. 14(2), 160-170 (2014).
71. Lee S-C, Ng S-S, Oldenburg J et al. Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin. Pharmacol. Ther. 79(3), 197-205 (2006).
72. Limdi NA, Wadelius M, Cavallari L et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 115(18), 3827-3834 (2010).
73. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur. Heart J. 34(17), 1279-1291 (2013).
74. 1000 Genomes: A Deep Catalog of Human Genetic Variation. www.1000genomes.org
75. Hu K-Q, Freilich B, Brown RS, Brass C, Jacobson IM. Impact of Hispanic or Asian ethnicity on the treatment outcomes of chronic hepatitis C: results from the WIN-R trial. J. Clin. Gastroenterol. 45(8), 720-726 (2011).
76. Goncąlo M, Coutinho I, Teixeira V et al. HLA-B∗58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis in a Portuguese population. Br. J. Dermatol. 169(3), 660-665 (2013).
77. Niihara H, Kaneko S, Ito T et al. HLA-B∗58:01 strongly associates with allopurinol-induced adverse drug reactions in a Japanese sample population. J. Dermatol. Sci. 71(2), 150-152 (2013).
78. Cao Z, Wei Z, Zhu Q et al. HLA-B∗58:01 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese. Pharmacogenomics 13(10), 1193-1201 (2012).
79. Cristallo AF, Schroeder J, Citterio A et al. A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis. Int. J. Immunogenet. 38(4), 303-309 (2011).
80. Somkrua R, Eickman EE, Saokaew S, Lohitnavy M, Chaiyakunapruk N. Association of HLA-B∗5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. BMC Med. Genet. 12, 118 (2011).
81. Dekker JW, Nizankowska E, Schmitz-Schumann M et al. Aspirin-induced asthma and HLA-DRB1 and HLA-DPB1 genotypes. Clin. Exp. Allergy 27(5), 574-577 (1997).
82. Choi JH, Lee KW, Oh HB et al. HLA association in aspirinintolerant asthma: DPB1∗0301 as a strong marker in a Korean population. J. Allergy Clin. Immunol. 113(3), 562-564 (2004).
83. Lympany PA, Welsh KI, Christie PE, Schmitz-Schumann M, Kemeny DM, Lee TH. An analysis with sequence-specific oligonucleotide probes of the association between aspirininduced asthma and antigens of the HLA system. J. Allergy Clin. Immunol. 92(1 Pt 1), 114-123 (1993).
84. Niihara H, Kakamu T, Fujita Y, Kaneko S, Morita E. HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepineinduced lymphocyte proliferation in a Japanese population. J. Dermatol. 39(7), 594-601 (2012).
85. Hung S-I, Chung W-H, Jee S-H et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet. Genomics 16(4), 297-306 (2006).
86. Shi Y-W, Min F-L, Qin B et al. Association between HLA and Stevens-Johnson syndrome induced by carbamazepine in Southern Han Chinese: genetic markers besides B∗1502? Basic Clin. Pharmacol. Toxicol. 111(1), 58-64 (2012).
87. Hsiao Y-H, Hui RC-Y, Wu T et al. Genotype-phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: strength and clinical correlations. J. Dermatol. Sci. 73(2), 101-109 (2014).
88. Genin E, Chen D-P, Hung S-I et al. HLA-A∗31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis. Pharmacogenomics J. 14(3), 281-288 (2014).
89. Lieberman JA, Yunis J, Egea E, Canoso RT, Kane JM, Yunis EJ. HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch. Gen. Psychiatry 47(10), 945-948 (1990).
90. Yunis JJ, Corzo D, Salazar M, Lieberman JA, Howard A, Yunis EJ. HLA associations in clozapine-induced agranulocytosis. Blood 86(3), 1177-1183 (1995).
91. Valevski A, Klein T, Gazit E et al. HLA-B38 and clozapineinduced agranulocytosis in Israeli Jewish schizophrenic patients. Eur. J. Immunogenet. 25(1), 11-13 (1998).
92. Athanasiou MC, Dettling M, Cascorbi I et al. Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. J. Clin. Psychiatry 72(4), 458-463 (2011).
93. Amar A, Segman RH, Shtrussberg S et al. An association between clozapine-induced agranulocytosis in schizophrenics and HLA-DQB1∗0201. Int. J. Neuropsychopharmacol. 1(1), 41-44 (1998).
94. Seto W-K, Tsang OT-Y, Liu K et al. Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection. J. Viral Hepat. 20(7), 470-477 (2013).
95. Motomura T, Shirabe K, Furusyo N et al. Effect of laparoscopic splenectomy in patients with Hepatitis C and cirrhosis carrying IL28B minor genotype. BMC Gastroenterol. 12, 158 (2012).
96. Ogawa E, Furusyo N, Nakamuta M et al. Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy. J. Hepatol. 59(4), 667-674 (2013).
97. Rembeck K, Waldenström J, Hellstrand K et al. Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3. Hepatology 59(6), 2131-2139 (2014).
98. Hwang J-J, Lo C-C, Lin C-H et al. Association between IPTA gene polymorphisms and hematological abnormalities in hepatitis C virus-infected patients receiving combination therapy. Gut Liver 8(6), 605-611 (2014).
99. Holmes JA, Roberts SK, Ali RJ et al. ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response. Hepatology 59(6), 2152-2160 (2014).
100. Clark PJ, Aghemo A, Degasperi E et al. Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy. J. Viral Hepat. 20(12), 858-866 (2013).
101. D'Avolio A, De Nicolò A, Cusato J et al. Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients. Antiviral Res. 100(1), 114-119 (2013).
102. Tsubota A, Shimada N, Abe H et al. Several factors including ITPA polymorphism influence ribavirin-induced anemia in chronic hepatitis C. World J. Gastroenterol. 18(41), 5879-5888 (2012).
103. D'Avolio A, Ciancio A, Siccardi M et al. Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment. Ther. Drug Monit. 34(2), 165-170 (2012).
104. Naggie S, Rallon NI, Benito JM et al. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes. J. Infect. Dis. 205(3), 376-383 (2012).
105. Thompson AJ, Fellay J, Patel K et al. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology 139(4), 1181-1189 (2010).
106. Suzuki F, Suzuki Y, Akuta N et al. Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Hepatology 53(2), 415-421 (2011).
107. Thompson AJ, Santoro R, Piazzolla V et al. Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. Hepatology 53(2), 389-395 (2011).
108. Lee A-Y, Kim M-J, Chey W-Y, Choi J, Kim B-G. Genetic polymorphism of cytochrome P450 2C9 in diphenylhydantoin-induced cutaneous adverse drug reactions. Eur. J. Clin. Pharmacol. 60(3), 155-159 (2004).
109. Ikeda M, Kondo K, Iwata N. Variant GADL1 and response to lithium in bipolar I disorder. N. Engl. J. Med. 370(19), 1856-1857 (2014).
110. Consortium on Lithium Genetics, Hou L, Heilbronner U et al. Variant GADL1 and response to lithium in bipolar I disorder. N. Engl. J. Med. 370(19), 1857-1859 (2014).
111. Kotambail A, Mathur A, Bhat SM, Rai PS, Sharma PS, Satyamoorthy K. GADL1 gene polymorphisms and lithium response in bipolar I disorder: lack of association from an Indian population. Psychiatr. Genet. 25(1), 39-40 (2015).
112. Caudle KE, Rettie AE, Whirl-Carrillo M et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin. Pharmacol. Ther. 96(5), 542-548 (2014).
113. Leckband SG, Kelsoe JR, Dunnenberger HM et al. Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing. Clin. Pharmacol. Ther. 94(3), 324-328 (2013).
114. Relling M V, Gardner EE, Sandborn WJ et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin. Pharmacol. Ther. 89(3), 387-391 (2011).
115. Takatsu N, Matsui T, Murakami Y et al. Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease. J. Gastroenterol. Hepatol. 24(7), 1258-1264 (2009).
116. Ross CJD, Katzov-Eckert H, Dubé M-P et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat. Genet. 41(12), 1345-1349 (2009).
117. Pussegoda K, Ross CJ, Visscher H et al. Replication of TPMT and ABCC3 genetic variants highly associated with cisplatininduced hearing loss in children. Clin. Pharmacol. Ther. 94(2), 243-251 (2013).
118. Kimmel SE, French B, Kasner SE et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N. Engl. J. Med. 369(24), 2283-2293 (2013).
119. Perera MA, Cavallari LH, Limdi NA et al. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet 382(9894), 790-796 (2013).
120. Cooper GM, Johnson JA, Langaee TY et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112(4), 1022-1027 (2008).
121. Takeuchi F, McGinnis R, Bourgeois S et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 5(3), e1000433 (2009).
122. Cha P-C, Mushiroda T, Takahashi A et al. Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. Hum. Mol. Genet. 19(23), 4735-4744 (2010).
123. Perera MA, Gamazon E, Cavallari LH et al. The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans. Clin. Pharmacol. Ther. 89(3), 408-415 (2011).
124. Daneshjou R, Gamazon ER, Burkley B et al. Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans. Blood 124(14), 2298-2305 (2014).
125. Teo YY, Ong RTH, Sim X, Tai E-S, Chia K-S. Identifying candidate causal variants via trans-population fine-mapping. Genet. Epidemiol. 34(7), 653-664 (2010).
126. Wu Y, Waite LL, Jackson AU et al. Trans-ethnic fine-mapping of lipid loci identifies population-specific signals and allelic heterogeneity that increases the trait variance explained. PLoS Genet. 9(3), e1003379 (2013).
127. Peters U, North KE, Sethupathy P et al. A systematic mapping approach of 16q12. 2/FTO and BMI in more than 20, 000 African Americans narrows in on the underlying functional variation: results from the Population Architecture using Genomics and Epidemiology (PAGE) study. PLoS Genet. 9(1), e1003171 (2013).
128. 1000 Genomes Project Consortium, Abecasis GR, Auton A et al. An integrated map of genetic variation from 1, 092 human genomes. Nature 491(7422), 56-65 (2012).
129. Li J, Lao X, Zhang C, Tian L, Lu D, Xu S. Increased genetic diversity of ADME genes in African Americans compared with their putative ancestral source populations and implications for pharmacogenomics. BMC Genet. 15, 52 (2014).
130. Ortega VE, Meyers DA. Pharmacogenetics: implications of race and ethnicity on defining genetic profiles for personalized medicine. J. Allergy Clin. Immunol. 133(1), 16-26 (2014).